Metastatic Non-Small Cell Lung Cancer
Also known as: Metastatic NSCLC - Non-Small Cell Lung Cancer / Metastatic Non-small Cell Lung Cancers / Metastatic Nonsmall Cell Lung Cancer / Metastatic NSCLC / Metastatic Non-Small Cell Lung Carcinoma / Metastatic Non-small Cell Lung Cancer (NSCLC) / Non-small cell lung cancer metastatic / Metastatic non-small cell lung cancer (disorder) / Lung cancer non-small cell stage IV / Non-small cell lung cancer stage IV
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15568 | Adagrasib | A KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy. |
| DB08916 | Afatinib | An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy. |
| DB16695 | Amivantamab | An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation. |
| DB11595 | Atezolizumab | A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. |
| DB11967 | Binimetinib | A medication used to treat metastatic melanoma with specific mutations. |
| DB12267 | Brigatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| DB11791 | Capmatinib | A kinase inhibitor targeting c-Met receptor tyrosine kinase in the treatment of non-small cell lung cancer with MET exon 14 skipping. |
| DB14707 | Cemiplimab | A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. |
| DB08865 | Crizotinib | A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. |
| DB08912 | Dabrafenib | A kinase inhibitor used to treat patients with specific types of melanoma, non-small cell lung cancer, and thyroid cancer. |
| DB11963 | Dacomitinib | A medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. |
| DB11714 | Durvalumab | An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. |
| DB11718 | Encorafenib | A kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations. |
| DB11986 | Entrectinib | Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment... |
| DB00530 | Erlotinib | An EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
| DB00317 | Gefitinib | A tyrosine kinase inhibitor used as first-line therapy to treat non-small cell lung carcinoma (NSCLC) that meets certain genetic mutation criteria. |
| DB06186 | Ipilimumab | A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. |
| DB16216 | Lazertinib | A tyrosine kinase inhibitor used in combiantion with amivantamab to treat non-small cell lung cancer with EGFR mutations. |
| DB12130 | Lorlatinib | An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. |
| DB16390 | Mobocertinib | An oral kinase inhibitor targeted against EGFR and used in the treatment of NSCLC with EGFR exon 20 insertion mutations. |
| DB09559 | Necitumumab | A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer. |
| DB09035 | Nivolumab | A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. |
| DB09330 | Osimertinib | A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma. |
| DB01229 | Paclitaxel | A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer. |
| DB09037 | Pembrolizumab | A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. |
| DB05578 | Ramucirumab | An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. |
| DB15569 | Sotorasib | An experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer. |
| DB15133 | Tepotinib | An oral tyrosine kinase inhibitor targeted against MET for the treatment of metastatic non-small cell lung cancer in patients exhibiting MET exon 14 skipping mutations. |
| DB08911 | Trametinib | A kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer. |
| DB14962 | Trastuzumab deruxtecan | An antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. |
| DB11771 | Tremelimumab | An anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab. |
| DB00361 | Vinorelbine | A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC. |